What We Offer

Senior Medical Affairs Leadership Support Across Critical Inflection points

LUMARES supports biopharma organisations at critical inflection points, providing senior-level scientific and Medical Affairs leadership that strengthens decision-making, accelerates progress meaningfully, and drives measurable impact.

We work across three core moments:

1) Early-stage strategy and scientific positioning

2) Launch readiness and first-launch execution

3) Post-launch optimisation and indication expansion

This approach has been applied across multiple high-stakes global programmes, including building full global Medical Affairs launch readiness from a preclinical starting point in six months for one of the largest and most complex launches in pharmaceutical history.

Across critical inflection points, LUMARES supports organisations through a defined set of Medical Affairs capabilities. These are not delivered uniformly, but selectively, based on asset maturity, competitive context, organisational readiness, and launch ambition. We help leaders translate the right Medical Affairs capabilities to be deployed at the right time, for the right strategic purpose, leading to agile, measured impact.

Medical Affairs Strategy, Integrated Evidence & Launch Readiness

End-to-end Medical Affairs strategy
Early development through first launch
Launch readiness audits and build
Asset and portfolio-level Medical Affairs design
Medical strategy aligned to corporate objectives
Integrated Evidence planning (health economics, clinical and real world and outcomes evidence)

Scientific Engagement & Scientific Communications

Scientific platform and narrative development
Publications strategy
Congress strategy
Advisory boards
Medical information strategy
Integrated evidence narratives for regulators, HTA, and external stakeholders
Impact-driven scientific intelligence to inform medical and corporate strategy

Field Medical Leadership & Medical Excellence

Field Medical strategy and operating models
Medical Science Liaison capability design
Training and scientific excellence
Medical Performance frameworks
Impact and value measurement (proprietary to Lumares and used to demonstrate measurable corporate and medical outcomes)
Medical excellence models

Integrated Medical Capabilities & Operating Models

Integration across Medical Affairs, Regulatory, Pharmcovigilance, Medical Information, Health Economics and Outcomes Research (as part of Medical Affairs or not)
Medical governance and decision frameworks
Operating models and systems for scale, impact and speed
Cross-functional integration (R&D, Commercial, Corporate)
Preparing organisations for complexity, not just growth

Patient Advocacy & Disease Strategy

Early patient and advocacy landscape mapping
Strategic partnerships with patient organisations
Disease area strategy for novel or poorly understood conditions
Patient insight integration into medical strategy, clinical development and evidence planning
Disease awareness grounded in scientific and medical strategy to support long-term credibility, access, and value

Board-Level, Executive and Investor Advisory

Board-level scientific and medical input
Investor and due diligence support
Portfolio and pipeline prioritisation
Strategic pivots and acceleration
Funding and value inflection support
Policy- and guideline-informed strategy

Medical Affairs Decision Intelligence & AI-Enabled Insight

Medical Affairs is generating more data, insight, and activity than ever before yet many organisations struggle to translate this volume into clear, timely, and defensible decisions. Activity increases, but strategic signal is often lost in noise.

LUMARES supports organisations in applying AI and advanced analytics with purpose, ensuring these capabilities strengthen judgement, prioritisation, and accountability rather than fragmenting decision-making or accelerating the wrong actions.

Our focus is not on technology adoption for its own sake, but on how AI is governed, interpreted, and embedded within Medical Affairs strategy to support launch readiness, scientific differentiation, and long-term credibility.

We support organisations by:

Defining where AI-enabled insight meaningfully supports Medical Affairs decision-making across strategy, evidence, engagement, and performance
Translating fragmented insights (scientific exchange, evidence generation, medical information, field activity) into coherent, decision-ready narratives with impact
Supporting insight prioritisation and signal-to-noise reduction to focus Medical Affairs on the decisions that matter most at critical inflection points
Embedding AI-enabled approaches into existing Medical Affairs operating models, rather than creating parallel or disconnected system

This offering is designed for organisations seeking to:

Strengthen decision quality and confidence in complex, high-stakes environments
Improve the strategic use of Medical Affairs insight for launch readiness and portfolio prioritisation
Ensure AI adoption enhances scientific leadership, credibility, and impact rather than eroding them

LUMARES supports Medical Affairs strategy and launch readiness by:

- Designing end-to-end Medical Strategy aligned to asset, portfolio, and corporate objectives

- Integrating evidence, scientific engagement, and value narratives early

- Supporting differentiated launch readiness for both novel and next-in-class products

- Building and scaling Medical Affairs capabilities and/or functions fit for pace, scrutiny, and growth

- Stress-testing readiness against real regulatory, health technology, and external expectations

This service is designed for organisations:

- Approaching high-risk launches

- Scaling novel or first-in-class platforms, or looking for a scientific differentiation launc

- Undergoing strategic, organisational, or portfolio transition

Why the right Medical Affairs Capabilities are Critical for your Organisation's Success

For novel, first-in-class technologies and those products needing firm scientific differentiation, the difference between momentum and friction is rarely execution alone: it is the quality of evidence and whether Medical Affairs is designed to support them.

Too often, Medical Affairs comes along reactively, fragmented across strategy, evidence, engagement, and operations. Activity increases, but impact both internally and externally, does not. By the time organisations approach launch or critical inflection points, Medical Affairs is busy, but not impact-ready. for the needs of external stakeholders or to support market access value.

Medical Affairs plays a critical role in launch readiness, but only when the right capabilities are deployed for the right asset, region, and strategic objective. Activity alone does not create readiness, and capability without alignment does not create impact.

Having extensively operated within global regulatory, payer, and health technology discussions shaping expectations for new technologies, we understand not only what is required but why those requirements exist and how they are applied in practice. We understand how to launch products with success and impact across all domains of Medical Affairs and to provide measurable impact across unmet medical needs, to senior corporate stakeholders and investors.

That is why LUMARES is structured to support organisations at the moments where decisions, evidence, and credibility determine outcomes.